Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility in Tamil Nadu with an investment of $1 Billion/Rs 100 Crore.
The company plans to invest in its existing facility in Thiruvallur District. Natco Pharma is investing $1 Billion/Rs 100 Crore in the facility to manufacture 16 campaign products at a time.
The company will manufacture products with a production capacity of 66.32 tonnes per annum from existing production capacity of 46.267 tonnes per annum.
The expansion will be done in a total land span across 10.57 hectares that is in the control of the company.
API facility expansion is to meet the growing market demand for pharmaceutical products in the country. Nearly 350 direct and 100 indirect jobs will be created with the proposed expansion.
The proposed products will be manufactured on the basis of proven technologies from in-house R&D and private consultants for the cost-effective and environmentally friendly practices.
Natco develops APIs for captive consumption of its Finished Dosage Formulation portfolio as well as third-party sales.
The company is focused majorly on complex molecules in oncology and CNS segments. Other therapeutic areas of focus include anti-asthmatic, anti-depressant, anti-migraine, anti-osteoporosis and gastrointestinal disorders.
The API R&D expansion will help the company broaden its API portfolio in the coming years and with manufacturing capacities at both locations Mekaguda and Manali set to double in the next two years.
The company is planning to expand customer base and penetrate into new markets making concrete business development efforts.
|Tamil Nadu, India
|$1 Billion/Rs 100 Crore